Contract Services
Samabriva Accelerates its Growth With New State-of-the-Art Biomanufacturing Facility
Samabriva recently announced the opening of a new 1,400 m² biomanufacturing facility in Liege, Belgium, at the heart of European’s biotech valley. This strategic investment…
SGS Laboratory in Ireland Gains Platinum My Green Lab Certification
SGS, the world’s leading testing, inspection and certification company, is proud to announce that its laboratory in Ringaskiddy, Cork, Ireland, has received platinum certification under…
Lonza Launches Tailored Offering for Smart Capsules Companies Developing Oral Delivery Solutions for Biologic Drugs
Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, recently announced an expansion of its service offering for orally delivered biologic therapies…
Veranova Recognized as One of SOCMA’s 25 Companies for Industry-Leading Safety Programs
Veranova recently announced it has been recognized by The Society of Chemical Manufacturers & Affiliates, Inc. (SOCMA) as a recipient of its prestigious 2024 Safety…
Marinomed Biotech AG Signs Agreement for Sale of Carragelose Business to Unither Pharmaceuticals
Marinomed Biotech AG has signed an agreement on the sale of its Carragelose business to the French CDMO Unither Pharmaceuticals. The contract provides for upfront…
Nutriband Receives Patent Notice of Publication for its Abuse Deterrent Transdermal Technology
Nutriband Inc. recently announced it has received a Notice of Publication of the Registration and Grant of a Standard Patent (R) from the Hong Kong…
Hovione Expands Global Spray Drying Capacity With Significant Investment in the US & Ireland
Hovione just completed significant expansions in Europe and the US. The investments at its East Windsor, NJ, and Ringaskiddy, Cork, facilities will significantly increase Hovione's…
ACG Launches Innovative Tablet Feeder
ACG Engineering, a division of ACG, a leading supplier of integrated manufacturing solutions to the global pharmaceutical and nutraceutical industries, unveiled its new ADAPT X…
Adragos Pharma Acquires Leading Swiss Sterile Fill-Finish Expert
Adragos Pharma has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing. This acquisition significantly enhances Adragos’ sterile manufacturing capabilities and marks a pivotal step…
CASE STUDY - Overcoming Barriers to Patient Adherence With A Novel Dosage Form
In this CPHI Award-winning case study, learn how Adare scientists took the alternative sprinkle version out of the lab and into the hands of patients.
ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products
Adare’s team of nitrosamine experts have developed a straightforward framework that simplifies the identification of at-risk APIs.
Bormioli Pharma Invents The Open & Collaborative Innovation Platform for the Pharmaceutical Packaging of the Future
Bormioli Pharma, a global leader in the production of containers for pharmaceutical use and medical devices, has always been a promoter of innovation, which translates…
Vetter Strengthens Senior Management Team for Further Sustainable Growth
Vetter recently announced the appointment of three senior leaders to take on the role of managing directors alongside Thomas Otto and Peter Soelkner. As of…
Abzena Expands Analytical Capabilities to Include GMP Cell-Based Potency Testing Across US & UK Sites
Abzena recently announced the expansion of their early and late phase analytical capabilities to now include GMP cell-based potency assays at their Cambridge, UK and San…
Lonza Announces First GMP Batch Completion at Next-Generation Mammalian Manufacturing Facility in Portsmouth (US)
Lonza, a global development and manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, today announced the completion of the first GMP product batch supported…
Genezen Appoints New Chief Operations Officer
Genezen recently announced the appointment of Mike Wourms as Chief Operations Officer. This appointment bolsters Genezen’s strategic growth plan and comes at a time of…
PCI Pharma Services & ChiRhoClin Partner to Prevent Shortage of Critical Orphan Pancreatic Drug
PCI Pharma Services (PCI) is collaborating with theranostics specialist ChiRhoClin, Inc. to avoid the potential shortage of a critical diagnostic drug used to test for…
Ardena’s New State-of-the-Art Nanomedicine Facility Secures Full GMP Approval for Manufacturing
Ardena recently announces the full Good Manufacturing Practice (GMP) approval of its expanded nanomedicine facility in Oss. Granted by the Dutch Healthcare Authority, the approval enables…
Gattefossé Announces Inauguration of its New Premises & Technical Center of Excellence in Mumbai
India is a strategic country for the business development of the Gattefossé Group. To support this growing market, Gattefossé continues to invest in the opening…
Quotient Sciences Announces Installation of World's First GMP Biofoundry-in-a-Box From Centillion Technology
Quotient Sciences recently announced the installation of Centillion’s proprietary Biofoundry-in-a-Box (BiaB), the first multi-product GMP platform technology for end to end RNA manufacture. BiaB is…
Contract Services Market Overview
Increasing patent expirations of major drugs, the growing burden of chronic diseases, and elevated global awareness of vaccines are leading to a surge in outsourcing formulation development services. Industry experts say these trends put a value on the global pharmaceutical CDMO Market at $160.12 billion in 2020, and could reach $236.61 billion by 2026, while the North American CDMO market is expected to reach $101.1 billion by 2030. As more pharma/biopharma companies opt to partner with CDMOs, much of this activity is occurring in the early phase of development with the goal of overcoming risk, along with saving time and money as a drug passes through the development pipeline.
Sectors of the CDMO market – sterile injectables, prefilled syringes, biologics APIs, and viral vectors – are expected to expand quickly, driven by an accelerating shift in the pharmaceutical market toward innovative biologic and cell and gene therapy products. Nonetheless, small molecules will continue to represent the majority of prescribed drugs for the foreseeable future and thus are the major growth driver for the CDMO market.
Who Uses Contract Services?
Experts see a strong correlation between size of a company and its likelihood to outsource. In 2017, manufacturing of 20% of newly approved drugs was outsourced by Big Pharma; this increases to 80% of all manufacturing being contracted out by small biotech/pharma. And all 15 newly approved drugs in 2017 owned by small companies were supplied by CDMOs.
Rare diseases, fast-tracked drugs, and oncology treatments now account for much of pharma’s development pipeline, so it is important that CDMOs provide specialized capabilities, technology, expertise, and experience relevant to these types of programs. For expedited pathways, it is important, too, that development partners understand the interwoven and related steps essential to progressing a program efficiently and quickly. To that end companies have invested in technology and capabilities such as hot melt extrusion, spray-dry dispersions, and lipid formulation to provide options for small-molecule development, often to address the all-too-common hurdle of poor solubility and bioavailability.
How to Work with Contract Service Providers
Getting a CDMO engaged in the development process as early as possible avoids spending time exploring the wrong solutions and coming up with suboptimal formulations that need to be corrected before manufacturing. By bringing a CDMO in earlier in the process, they can more accurately assess which technologies and approaches can work on a project.
As drug products become more complex, there is increasing customer demand for relationships with CDMOs that have core competencies in highly specialized formulation and process technology areas.
One of these specialty areas is complex molecules. Biotech companies developing novel biologics are increasing in the market, thus there is an increase in outsourcing development services to BioCDMOs. To serve the needs of this market, companies are expanding their bio capabilities to offer advanced manufacturing technologies.
Another area of expertise where pharma is relying on CDMOs is in cell and gene therapy. Industry insiders expect gene therapy manufacturing market to boom and grow at rates ranging from 15 to 20%. Benefits of partnering with a cell or gene therapy CDMO include scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies. Demand for specialized manufacturing and clinical trial support for cell and gene therapies has resulted in more than 40 companies offering these services.